Monocyte Activation Drives Atrial Fibrillation in Hypertension.

IF 3.5 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiovascular Drugs and Therapy Pub Date : 2026-10-01 Epub Date: 2026-03-21 DOI:10.1007/s10557-026-07867-6
Qian-Wan Deng, Zi-Qi Xu, Wei Zhang, Yuan-Yuan Kang, Wu-Wei Rong, Jia-Hui Xia, Ping-Jin Gao, Xiao-Dong Li, Ji-Guang Wang
{"title":"Monocyte Activation Drives Atrial Fibrillation in Hypertension.","authors":"Qian-Wan Deng, Zi-Qi Xu, Wei Zhang, Yuan-Yuan Kang, Wu-Wei Rong, Jia-Hui Xia, Ping-Jin Gao, Xiao-Dong Li, Ji-Guang Wang","doi":"10.1007/s10557-026-07867-6","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1793-1808"},"PeriodicalIF":3.5000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-026-07867-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
高血压患者单核细胞活化导致心房颤动。
背景:心房颤动(AF)是最常见的心律失常,高血压是其主要危险因素。虽然已知免疫功能障碍在高血压中起关键作用,但其对高血压背景下房颤的具体影响仍未得到充分探讨。本研究旨在阐明AF在高血压背景下的免疫格局,并探讨其潜在机制。方法:采用单细胞RNA转录组学分析方法对高血压合并房颤患者外周血单个核细胞(PBMCs)进行分析,并以无房颤的高血压患者为对照。流式细胞术、血清细胞因子分析和队列研究用于验证。结果:单核细胞被确定为高血压合并房颤患者中受影响最显著的细胞类型,显示出胆固醇稳态和免疫炎症反应的高度破坏。有趣的是,一种独特的单核细胞-血小板聚集(MPAs)簇被确定为表现出最活跃的细胞间相互作用。流式细胞术证实高血压房颤患者中CD14+单核细胞和MPAs的比例升高。更大队列的血清分析显示,C-C基序趋化因子配体2 (CCL2)水平显著升高,也称为单核细胞趋化蛋白-1 (MCP-1)和白细胞介素-6 (IL-6)。来自血液和心脏组织的单细胞数据的整合揭示了高血压合并房颤患者单核细胞募集和分化增加的转录模式。队列研究进一步支持循环单核细胞数量增加与高血压患者房颤发生率升高相关。结论:我们的研究表明,单核细胞激活介导的炎症反应可能在高血压房颤的发病机制中发挥重要作用。这些发现为管理高血压患者房颤的潜在治疗靶点提供了新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular Drugs and Therapy
Cardiovascular Drugs and Therapy 医学-心血管系统
CiteScore
8.30
自引率
0.00%
发文量
110
审稿时长
4.5 months
期刊介绍: Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients. Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书